Literature DB >> 20441530

Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems.

Ewa Pomianowska1, Ivar P Gladhaug, Krzysztof Grzyb, Bård I Røsok, Bjørn Edwin, Deidi S Bergestuen, Oystein Mathisen.   

Abstract

OBJECTIVE: The aim of this study was to delineate the clinical outcomes and pathological characteristics of surgically resected endocrine tumors of the pancreas and to determine the importance of the World Health Organization (WHO) and tumor-node metastasis (TNM) classifications, resection status, and Ki-67 expression for long-term survival. PATIENTS AND METHODS: Sixty-nine patients underwent surgical tumor resection with curative intent during 1990-2007. Hospital records were reviewed retrospectively for medical, surgical, pathological, and radiological data.
RESULTS: Forty-one patients (59%) had non-functional tumors, 28 (41%) patients had functional tumors. Thirty-seven (54%) tumors were classified as WHO group 1 and the remaining 32 as WHO group 2. There were no poorly differentiated endocrine carcinomas. The overall R0-resection rate was 68%. Patients in whom all gross tumor was resected (R0/R1) had significantly better survival compared to patients with macroscopic residual disease (R2) (p < 0.001). There was no difference in survival between patients with R0 and R1 resections. Both the WHO (p < 0.001) and the TNM (p < 0.001) classifications significantly predicted five and 10-year survival after resection of the primary tumor. Survival analysis revealed significantly better outcome for patients with tumors with Ki-67 index < 2% (p = 0.003).
CONCLUSIONS: Both WHO and TNM classifications reliably predict long-term survival in patients with resectable pancreatic endocrine tumors. R2 resection status predicted poor prognosis. R0 status did not improve prognosis relative to R1 status. Ki-67 index > 2% is a predictor of poor long-term survival.

Entities:  

Mesh:

Year:  2010        PMID: 20441530     DOI: 10.3109/00365521003782363

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  14 in total

Review 1.  Surgical resection of pancreatic neuroendocrine neoplasm by minimally invasive surgery-the robotic approach?

Authors:  Roxanne Y A Teo; Brian K P Goh
Journal:  Gland Surg       Date:  2018-02

2.  Long-term outcome of laparoscopic surgery for pancreatic neuroendocrine tumors.

Authors:  Sven-Petter Haugvik; Irina Pavlik Marangos; Bård Ingvald Røsok; Ewa Pomianowska; Ivar Prydz Gladhaug; Oystein Mathisen; Bjørn Edwin
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

Review 3.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 4.  Pancreatic neuroendocrine tumors.

Authors:  Jian Sun
Journal:  Intractable Rare Dis Res       Date:  2017-02

5.  Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry.

Authors:  Ioannis Mintziras; Tobias Keck; Jens Werner; Stefan Fichtner-Feigl; Uwe Wittel; Norbert Senninger; Thorsten Vowinkel; Jörg Köninger; Matthias Anthuber; Bernd Geißler; Detlef Klaus Bartsch
Journal:  Surg Today       Date:  2019-06-25       Impact factor: 2.549

Review 6.  Update on surgical treatment of pancreatic neuroendocrine neoplasms.

Authors:  Jan G D'Haese; Chiara Tosolini; Güralp O Ceyhan; Bo Kong; Irene Esposito; Christoph W Michalski; Jörg Kleeff
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 7.  The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant.

Authors:  Irvin M Modlin; Steven F Moss; Bjorn I Gustafsson; Ben Lawrence; Simon Schimmack; Mark Kidd
Journal:  Langenbecks Arch Surg       Date:  2011-04-27       Impact factor: 3.445

Review 8.  Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances.

Authors:  Tetsuhide Ito; Hisato Igarashi; Robert T Jensen
Journal:  J Gastroenterol       Date:  2012-08-11       Impact factor: 7.527

9.  Parenchyma-sparing resections for pancreatic neuroendocrine tumors.

Authors:  Rim Cherif; Sébastien Gaujoux; Anne Couvelard; Safi Dokmak; Marie-Pierre Vuillerme; Philippe Ruszniewski; Jacques Belghiti; Alain Sauvanet
Journal:  J Gastrointest Surg       Date:  2012-08-22       Impact factor: 3.452

10.  Pancreatic insulinoma combined with glucagon positive cell: A case report.

Authors:  Suguru Yamashita; Nobutaka Tanaka; Michiro Takahashi; Motoki Nagai; Takatoshi Furuya; Yoshio Suzuki; Yukihiro Nomura
Journal:  World J Gastrointest Surg       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.